AQSTAquestive Therapeutics, Inc.
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -97% · now 36% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AQST take a bad year?
Aquestive Therapeutics, Inc. holds $43M more cash than debt, and is burning $11M a quarter, about 2.1 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 2.1 years
Cash runway · burning $11M a quarter at the current rate
- Annualised volatility
- 76%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $55M
- Cash and short-term investments
- $98M
- Net cash
- $43M
- EBITDA, trailing twelve months
- −$52M
- Operating profit, trailing twelve months
- −$53M
- Annualised volatilitytwo years of daily moves
- 76%
- Worst drawdown on file
- −97%
- Below its 52-week high
- 36%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #37 of 41 by RyuScore